Medgenics Key Patent Claims Allowed in Japan Protecting Core Technology to be Used in Hepatitis Treatment

[Business Wire] – MISGAV, Israel & SAN FRANCISCO–(BUSINESSWIRE)– Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic … more

View todays social media effects on MDGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medgenics is hiring next, click here to view